Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Profile

Anthony Elias

Concepts (664)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
108
2024
2249
6.160
 Why?
Antineoplastic Combined Chemotherapy Protocols
96
2025
1695
4.160
 Why?
Sarcoma
33
2025
192
3.900
 Why?
Receptors, Estrogen
22
2021
435
2.350
 Why?
Triple Negative Breast Neoplasms
14
2024
202
2.290
 Why?
Receptor, ErbB-2
22
2024
342
2.050
 Why?
Hematopoietic Stem Cell Transplantation
36
2011
614
2.020
 Why?
Carcinoma, Small Cell
19
2003
172
1.740
 Why?
Soft Tissue Neoplasms
14
2022
116
1.600
 Why?
Carcinoma, Ductal, Breast
7
2018
83
1.510
 Why?
Neoadjuvant Therapy
17
2024
405
1.350
 Why?
Antineoplastic Agents
31
2023
2145
1.250
 Why?
Neoplasm Recurrence, Local
20
2022
1060
1.180
 Why?
Neoplasm Staging
35
2024
1377
1.070
 Why?
Receptors, Progesterone
13
2020
349
1.060
 Why?
Lung Neoplasms
38
2003
2494
1.040
 Why?
Combined Modality Therapy
52
2024
1241
1.020
 Why?
Doxorubicin
24
2025
368
1.020
 Why?
Biomarkers, Tumor
17
2022
1279
0.980
 Why?
Paclitaxel
14
2024
231
0.920
 Why?
CTLA-4 Antigen
1
2025
99
0.920
 Why?
Mastectomy
9
2018
139
0.920
 Why?
Bone Marrow Transplantation
27
1998
286
0.910
 Why?
Bone Neoplasms
7
2025
250
0.860
 Why?
Antibodies, Monoclonal, Humanized
10
2025
807
0.840
 Why?
Antineoplastic Agents, Alkylating
5
2018
73
0.760
 Why?
Female
168
2025
73162
0.750
 Why?
Receptors, Androgen
7
2018
149
0.740
 Why?
Disease-Free Survival
24
2023
690
0.720
 Why?
Humans
226
2025
137514
0.710
 Why?
Middle Aged
112
2025
33355
0.690
 Why?
Antineoplastic Agents, Hormonal
10
2018
161
0.680
 Why?
Maytansine
3
2021
16
0.660
 Why?
Liposarcoma
4
2023
26
0.660
 Why?
Adult
114
2025
37821
0.610
 Why?
Neoplasm Metastasis
23
2024
659
0.610
 Why?
Chemotherapy, Adjuvant
23
2023
392
0.600
 Why?
Dioxoles
2
2015
9
0.570
 Why?
Tetrahydroisoquinolines
2
2015
8
0.570
 Why?
Cyclophosphamide
31
2024
251
0.570
 Why?
Aged
65
2025
23798
0.530
 Why?
Ifosfamide
19
1998
37
0.520
 Why?
Androgen Receptor Antagonists
6
2021
34
0.520
 Why?
Phenylthiohydantoin
5
2017
42
0.520
 Why?
Dasatinib
1
2016
54
0.510
 Why?
Trastuzumab
10
2024
101
0.500
 Why?
Neoplasms, Hormone-Dependent
3
2012
38
0.490
 Why?
Treatment Outcome
43
2024
10821
0.480
 Why?
Drug Administration Schedule
24
2018
784
0.460
 Why?
Carboplatin
21
2016
144
0.450
 Why?
Estrogen Receptor alpha
5
2021
144
0.450
 Why?
Granulocyte Colony-Stimulating Factor
11
2002
74
0.450
 Why?
Carcinoma, Non-Small-Cell Lung
17
2001
1079
0.430
 Why?
Clinical Trials as Topic
19
2018
1047
0.420
 Why?
Estrogens
6
2018
361
0.410
 Why?
Dacarbazine
9
2018
97
0.400
 Why?
Survival Rate
19
2021
1980
0.370
 Why?
Tamoxifen
9
2018
202
0.370
 Why?
Neoplasms
20
2009
2666
0.370
 Why?
Survival Analysis
23
2010
1320
0.360
 Why?
Prognosis
22
2021
4031
0.350
 Why?
Venous Thromboembolism
3
2020
313
0.350
 Why?
Reverse Transcriptase Polymerase Chain Reaction
1
2013
974
0.350
 Why?
Pyrimidines
3
2020
472
0.350
 Why?
Programmed Cell Death 1 Receptor
2
2025
252
0.350
 Why?
Carcinoma, Intraductal, Noninfiltrating
3
2022
56
0.340
 Why?
Neoplasms, Second Primary
3
2022
115
0.340
 Why?
Antibodies, Monoclonal
9
2024
1428
0.340
 Why?
Dose-Response Relationship, Drug
17
2017
2066
0.340
 Why?
Granulocyte-Macrophage Colony-Stimulating Factor
8
1999
152
0.330
 Why?
Taxoids
7
2023
104
0.330
 Why?
Remission Induction
16
2002
287
0.330
 Why?
Breast Neoplasms, Male
3
2018
28
0.320
 Why?
Drug Resistance, Neoplasm
7
2017
806
0.310
 Why?
Gene Expression Regulation, Neoplastic
11
2018
1402
0.300
 Why?
Neoplastic Cells, Circulating
2
2020
80
0.300
 Why?
Mesna
12
1998
16
0.290
 Why?
Sarcoma, Ewing
3
2022
95
0.270
 Why?
Leiomyosarcoma
2
2018
28
0.270
 Why?
Cisplatin
14
2000
318
0.260
 Why?
Immunoconjugates
3
2024
116
0.260
 Why?
Sternum
1
2006
25
0.260
 Why?
Immunohistochemistry
5
2016
1740
0.250
 Why?
Tumor Microenvironment
4
2024
682
0.250
 Why?
Mastectomy, Segmental
2
2009
93
0.240
 Why?
Pyridines
2
2025
508
0.240
 Why?
Chondrosarcoma
1
2025
17
0.240
 Why?
Peripheral Blood Stem Cell Transplantation
2
2002
24
0.240
 Why?
Carcinoma, Ductal
1
2005
11
0.240
 Why?
Melphalan
10
2002
35
0.230
 Why?
Transplantation, Autologous
19
2002
238
0.230
 Why?
Male
66
2025
67718
0.230
 Why?
Isocitrate Dehydrogenase
1
2025
60
0.230
 Why?
Cell Adhesion Molecules
2
2021
183
0.230
 Why?
Protein Kinase Inhibitors
4
2019
920
0.230
 Why?
Lymph Nodes
1
2007
493
0.230
 Why?
Carcinoma
2
2008
237
0.220
 Why?
Glycine
1
2025
175
0.220
 Why?
Risk Reduction Behavior
2
2016
220
0.220
 Why?
Drug Evaluation
19
1998
84
0.220
 Why?
Adjuvants, Immunologic
3
2022
226
0.220
 Why?
Deoxycytidine
4
2020
176
0.210
 Why?
Ribonuclease III
2
2016
40
0.210
 Why?
Ovarian Neoplasms
3
2022
563
0.210
 Why?
Hodgkin Disease
4
2016
139
0.210
 Why?
Survivors
3
2016
489
0.210
 Why?
Thiotepa
13
2002
20
0.210
 Why?
Alkylating Agents
3
2000
24
0.210
 Why?
Weight Loss
4
2016
770
0.200
 Why?
DEAD-box RNA Helicases
2
2016
76
0.200
 Why?
Triazoles
2
2022
151
0.200
 Why?
Behavior Therapy
2
2016
262
0.200
 Why?
Aged, 80 and over
14
2021
7593
0.200
 Why?
Medical Oncology
5
2024
290
0.200
 Why?
Gene Expression Profiling
6
2017
1770
0.200
 Why?
Employment
1
2024
177
0.200
 Why?
Disease Management
5
2020
625
0.200
 Why?
Overweight
3
2016
554
0.190
 Why?
Obesity
4
2018
2974
0.190
 Why?
Salvage Therapy
6
2010
143
0.190
 Why?
Mutation
4
2025
3964
0.190
 Why?
Circulating Tumor DNA
1
2022
34
0.190
 Why?
Hydrazines
1
2022
35
0.190
 Why?
Carcinoma in Situ
2
2012
49
0.190
 Why?
Etoposide
10
2001
157
0.190
 Why?
Referral and Consultation
1
2007
780
0.180
 Why?
Hematologic Diseases
6
2008
62
0.180
 Why?
Emergency Medicine
1
2024
224
0.180
 Why?
Tumor Cells, Cultured
9
2020
957
0.180
 Why?
Liposarcoma, Myxoid
1
2021
10
0.180
 Why?
Sarcoma, Synovial
1
2021
21
0.180
 Why?
Aromatase Inhibitors
4
2021
53
0.180
 Why?
Recombinant Fusion Proteins
1
2024
665
0.180
 Why?
Endpoint Determination
1
2021
77
0.170
 Why?
Sentinel Lymph Node Biopsy
3
2017
116
0.170
 Why?
Cancer Care Facilities
1
2020
38
0.170
 Why?
Indazoles
1
2020
69
0.170
 Why?
Leukocytes, Mononuclear
3
2020
558
0.170
 Why?
Time Factors
12
2020
6817
0.170
 Why?
Hematopoietic Stem Cells
5
1996
398
0.170
 Why?
Cell Separation
3
2017
320
0.170
 Why?
Diphosphonates
1
2020
66
0.160
 Why?
Pyrroles
2
2013
211
0.160
 Why?
Bone Marrow
8
2000
286
0.160
 Why?
Diet
3
2018
1273
0.160
 Why?
Nuclear Medicine
1
2019
9
0.160
 Why?
Antigens, Neoplasm
4
2021
322
0.150
 Why?
Hematology
1
2019
20
0.150
 Why?
Proportional Hazards Models
6
2020
1263
0.150
 Why?
Cell Line, Tumor
9
2017
3420
0.150
 Why?
MCF-7 Cells
5
2017
127
0.150
 Why?
CA-125 Antigen
2
2013
14
0.150
 Why?
Fluorouracil
7
2013
213
0.150
 Why?
Epithelial-Mesenchymal Transition
1
2020
212
0.150
 Why?
Thromboembolism
1
2019
119
0.150
 Why?
Pulmonary Medicine
1
2019
85
0.150
 Why?
Nitriles
5
2017
175
0.150
 Why?
Benzamides
5
2017
218
0.150
 Why?
Receptor, Fibroblast Growth Factor, Type 1
1
2018
53
0.140
 Why?
Bayes Theorem
4
2024
407
0.140
 Why?
Cyclin-Dependent Kinase 4
1
2018
47
0.140
 Why?
Cyclin-Dependent Kinase 6
1
2018
42
0.140
 Why?
Research Design
3
2021
1116
0.140
 Why?
Tissue Inhibitor of Metalloproteinase-3
1
2017
9
0.140
 Why?
Infusions, Intravenous
10
2020
411
0.140
 Why?
Cell Cycle
1
2021
604
0.140
 Why?
Kaplan-Meier Estimate
6
2018
892
0.140
 Why?
Anesthesiology
1
2019
85
0.140
 Why?
Indoles
2
2013
415
0.140
 Why?
Schwann Cells
1
2017
34
0.140
 Why?
Tetrahydronaphthalenes
1
2017
29
0.140
 Why?
Sciatic Nerve
1
2017
58
0.140
 Why?
Microbubbles
1
2017
49
0.140
 Why?
Valine
1
2017
82
0.140
 Why?
Vaccines
1
2022
411
0.140
 Why?
Venous Thrombosis
1
2019
187
0.130
 Why?
Betacoronavirus
1
2020
268
0.130
 Why?
Societies, Medical
2
2019
820
0.130
 Why?
Camptothecin
3
2024
116
0.130
 Why?
Amyloid Precursor Protein Secretases
1
2017
81
0.130
 Why?
Lymph Node Excision
3
2015
174
0.130
 Why?
Axilla
3
2017
47
0.130
 Why?
Sulfonamides
1
2020
513
0.130
 Why?
Androgen Antagonists
2
2015
82
0.130
 Why?
Cancer-Associated Fibroblasts
1
2016
20
0.130
 Why?
Immunotherapy
2
2018
647
0.130
 Why?
Internship and Residency
2
2024
1131
0.130
 Why?
Gonadal Steroid Hormones
1
2018
139
0.130
 Why?
Hematopoietic Cell Growth Factors
2
1995
4
0.130
 Why?
Ultrasonography, Mammary
1
2016
13
0.130
 Why?
Neoplasms, Germ Cell and Embryonal
2
1995
77
0.130
 Why?
Neoplasms, Radiation-Induced
1
2016
92
0.130
 Why?
Thiazoles
1
2016
123
0.130
 Why?
Follow-Up Studies
6
2025
5139
0.120
 Why?
Antibody Specificity
1
2016
189
0.120
 Why?
Lymphatic Metastasis
3
2017
351
0.120
 Why?
Ambulatory Care
1
2020
539
0.120
 Why?
Neoplasm Invasiveness
3
2016
510
0.120
 Why?
Tumor Suppressor Protein p53
2
2023
531
0.120
 Why?
Myelin Sheath
1
2017
171
0.120
 Why?
Maximum Tolerated Dose
1
2016
199
0.120
 Why?
Antibiotics, Antineoplastic
1
2016
130
0.120
 Why?
Neoplastic Stem Cells
2
2017
398
0.120
 Why?
Benzimidazoles
1
2016
169
0.120
 Why?
Pneumonia, Viral
1
2020
368
0.120
 Why?
Quinolines
1
2016
180
0.120
 Why?
Coronavirus Infections
1
2020
359
0.120
 Why?
Recurrence
5
2020
1060
0.110
 Why?
Pyrazoles
1
2018
427
0.110
 Why?
Mammography
1
2016
151
0.110
 Why?
Drug Therapy, Combination
4
2014
1060
0.110
 Why?
Animals
17
2021
37011
0.110
 Why?
Radiotherapy, Adjuvant
5
2016
218
0.110
 Why?
Disease Progression
7
2018
2755
0.110
 Why?
Homeodomain Proteins
2
2018
504
0.110
 Why?
Administration, Oral
4
2020
814
0.110
 Why?
Antibodies
1
2016
414
0.110
 Why?
Brain Edema
1
2014
61
0.110
 Why?
Hepatic Veno-Occlusive Disease
3
2002
14
0.110
 Why?
Radiotherapy Dosage
3
1999
267
0.110
 Why?
Young Adult
10
2025
13243
0.110
 Why?
TOR Serine-Threonine Kinases
1
2017
414
0.110
 Why?
Exercise
2
2015
2024
0.110
 Why?
Vascular Neoplasms
1
2013
18
0.110
 Why?
Comorbidity
5
2017
1618
0.110
 Why?
Clinical Trials, Phase I as Topic
3
2024
51
0.110
 Why?
Radiotherapy
3
2015
201
0.100
 Why?
Testicular Neoplasms
1
1995
110
0.100
 Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2022
117
0.100
 Why?
Keratins
2
2017
173
0.100
 Why?
Epigenesis, Genetic
2
2018
660
0.100
 Why?
Cellular Reprogramming
1
2014
98
0.100
 Why?
Bridged-Ring Compounds
3
2020
14
0.100
 Why?
Mercaptoethanol
2
1990
11
0.100
 Why?
Mice
12
2021
17843
0.100
 Why?
Adenocarcinoma
6
2015
937
0.100
 Why?
Apoptosis
6
2023
2557
0.100
 Why?
Patient Selection
4
2016
691
0.100
 Why?
Gallium Radioisotopes
1
1992
14
0.100
 Why?
Bone Marrow Cells
4
2000
313
0.100
 Why?
Cell Proliferation
6
2017
2482
0.100
 Why?
Carmustine
10
2001
50
0.100
 Why?
Chromatin
1
2016
524
0.100
 Why?
Adolescent
23
2025
21555
0.100
 Why?
Protein-Tyrosine Kinases
2
2022
434
0.100
 Why?
Anthracyclines
3
2023
49
0.090
 Why?
Lymphoma, Non-Hodgkin
3
2001
88
0.090
 Why?
Methotrexate
4
2002
260
0.090
 Why?
Retrospective Studies
12
2023
15628
0.090
 Why?
Brain Neoplasms
5
2014
1241
0.090
 Why?
Weight Reduction Programs
1
2012
117
0.090
 Why?
Neoplasm, Residual
2
2022
133
0.090
 Why?
RNA, Catalytic
1
2012
186
0.090
 Why?
Polydeoxyribonucleotides
2
2002
14
0.090
 Why?
Risk Assessment
3
2020
3439
0.090
 Why?
Radiosurgery
1
2014
346
0.090
 Why?
Aorta
1
2013
421
0.090
 Why?
Neutropenia
5
2013
146
0.090
 Why?
Carcinoma, Lobular
1
2011
49
0.090
 Why?
Age Factors
5
2019
3301
0.090
 Why?
Neoplasm Grading
3
2017
308
0.090
 Why?
Leukapheresis
4
2001
21
0.090
 Why?
Multivariate Analysis
4
2013
1524
0.090
 Why?
Keratin-5
1
2010
50
0.080
 Why?
Angiogenesis Inhibitors
1
2012
226
0.080
 Why?
Liver Neoplasms
3
2015
786
0.080
 Why?
Biopsy
3
2018
1132
0.080
 Why?
Practice Patterns, Physicians'
1
2019
1312
0.080
 Why?
Peptide Mapping
1
2010
64
0.080
 Why?
Molecular Targeted Therapy
3
2018
414
0.080
 Why?
Electrophoresis, Gel, Two-Dimensional
1
2010
114
0.080
 Why?
Databases, Protein
1
2010
86
0.080
 Why?
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
1
2010
144
0.080
 Why?
Benzenesulfonates
1
2009
22
0.080
 Why?
Postmenopause
2
2017
361
0.080
 Why?
CD146 Antigen
2
2021
41
0.080
 Why?
Urinary Tract
1
1990
51
0.080
 Why?
BRCA2 Protein
1
2009
63
0.080
 Why?
Health Facilities
1
2009
83
0.080
 Why?
Pregnancy Complications, Neoplastic
1
2009
51
0.080
 Why?
Thrombophilia
1
2009
85
0.080
 Why?
Observer Variation
1
2010
347
0.080
 Why?
Patient Care
1
2009
111
0.070
 Why?
Risk Factors
8
2020
10356
0.070
 Why?
United States
9
2023
14696
0.070
 Why?
Perimenopause
1
2008
62
0.070
 Why?
Mice, Nude
3
2017
696
0.070
 Why?
Fibrinolytic Agents
2
2002
275
0.070
 Why?
Bone Marrow Diseases
4
2000
19
0.070
 Why?
In Situ Hybridization
2
2010
318
0.070
 Why?
Fatigue
3
2018
329
0.070
 Why?
In Situ Hybridization, Fluorescence
1
2008
319
0.070
 Why?
Randomized Controlled Trials as Topic
6
2000
1465
0.070
 Why?
Xenograft Model Antitumor Assays
3
2017
868
0.070
 Why?
Blotting, Western
1
2010
1227
0.070
 Why?
Pneumonectomy
3
1997
154
0.060
 Why?
Sputum
1
1988
311
0.060
 Why?
Reproducibility of Results
2
2016
3292
0.060
 Why?
Quality of Life
2
2015
2870
0.060
 Why?
Proto-Oncogene Proteins c-akt
2
2019
437
0.060
 Why?
Clinical Decision-Making
2
2020
321
0.060
 Why?
Neoplasm Proteins
2
2007
433
0.060
 Why?
Life Tables
2
2002
20
0.060
 Why?
Anilides
2
2016
73
0.060
 Why?
New Jersey
1
2024
14
0.060
 Why?
Positron-Emission Tomography
1
2006
299
0.060
 Why?
Colony-Stimulating Factors
3
1988
36
0.060
 Why?
Predictive Value of Tests
2
2016
2039
0.060
 Why?
Enzyme Inhibitors
1
2008
845
0.060
 Why?
Receptor, TIE-2
1
2024
12
0.060
 Why?
Granulocytes
4
1995
80
0.060
 Why?
Anticoagulants
2
2019
665
0.050
 Why?
New York
1
2024
133
0.050
 Why?
Genes, Neoplasm
1
2004
22
0.050
 Why?
Ricin
2
1997
8
0.050
 Why?
Growth Substances
3
1988
148
0.050
 Why?
Oligonucleotide Array Sequence Analysis
3
2012
765
0.050
 Why?
Patient Care Planning
1
2005
155
0.050
 Why?
Forecasting
3
2000
386
0.050
 Why?
MicroRNAs
1
2010
704
0.050
 Why?
Thrombocytopenia
3
2013
199
0.050
 Why?
Up-Regulation
2
2017
846
0.050
 Why?
Activating Transcription Factor 4
1
2023
20
0.050
 Why?
Proteasome Inhibitors
1
2023
45
0.050
 Why?
Mammaplasty
2
2016
113
0.050
 Why?
Signal Transduction
5
2018
5096
0.050
 Why?
Magnetic Resonance Imaging
1
2016
3722
0.050
 Why?
Proto-Oncogene Proteins c-mdm2
1
2023
66
0.050
 Why?
G(M2) Ganglioside
1
2022
1
0.050
 Why?
Injection Site Reaction
1
2022
3
0.050
 Why?
Cyclin E
1
2022
25
0.050
 Why?
Proteomics
1
2010
1113
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2000
105
0.050
 Why?
Transcriptome
2
2023
974
0.050
 Why?
Treatment Failure
2
2001
353
0.050
 Why?
France
2
2019
33
0.050
 Why?
Luminescent Measurements
1
2003
76
0.050
 Why?
Oncogene Proteins
1
2022
59
0.050
 Why?
Ribose
1
2022
23
0.050
 Why?
Blood Transfusion, Autologous
2
1993
17
0.050
 Why?
Proteasome Endopeptidase Complex
1
2023
156
0.050
 Why?
Carbolines
1
2022
32
0.050
 Why?
Heterocyclic Compounds, 4 or More Rings
1
2022
21
0.050
 Why?
Adenosine Diphosphate
1
2022
79
0.050
 Why?
Career Choice
1
2024
215
0.050
 Why?
Class I Phosphatidylinositol 3-Kinases
1
2022
95
0.050
 Why?
Actuarial Analysis
2
1993
27
0.050
 Why?
Oncogenes
1
2022
117
0.050
 Why?
Tomography, X-Ray Computed
2
2015
2681
0.050
 Why?
Colony-Forming Units Assay
4
1996
91
0.050
 Why?
Cell Division
2
2001
795
0.050
 Why?
Gene Expression
2
2020
1505
0.040
 Why?
Carcinoembryonic Antigen
1
2001
39
0.040
 Why?
Phthalazines
1
2021
45
0.040
 Why?
Fellowships and Scholarships
1
2024
306
0.040
 Why?
Prospective Studies
5
2022
7598
0.040
 Why?
Transplantation Immunology
1
2000
34
0.040
 Why?
Clodronic Acid
1
2020
17
0.040
 Why?
Longitudinal Studies
2
2012
2857
0.040
 Why?
Extracellular Matrix
1
2024
528
0.040
 Why?
Progesterone
1
2002
251
0.040
 Why?
Phosphatidylinositol 3-Kinases
1
2022
366
0.040
 Why?
Estradiol
2
2016
513
0.040
 Why?
Ligands
1
2022
665
0.040
 Why?
Topoisomerase I Inhibitors
1
1999
16
0.040
 Why?
Thoracotomy
2
1997
75
0.040
 Why?
Hematopoietic Stem Cell Mobilization
1
1999
22
0.040
 Why?
Polymerase Chain Reaction
1
2003
1061
0.040
 Why?
Leucovorin
2
1997
83
0.040
 Why?
Bone Density Conservation Agents
1
2020
80
0.040
 Why?
Dendritic Cells
2
2000
488
0.040
 Why?
Mechlorethamine
1
2000
60
0.040
 Why?
Myelodysplastic Syndromes
1
2001
135
0.040
 Why?
Drug Resistance
1
1999
170
0.040
 Why?
Neoplasms, Experimental
1
2000
176
0.040
 Why?
Heterocyclic Compounds, 3-Ring
1
2019
32
0.040
 Why?
Receptors, Steroid
1
2019
50
0.040
 Why?
Cluster Analysis
2
2012
502
0.040
 Why?
Piperazines
1
2021
351
0.040
 Why?
Cell Cycle Proteins
1
2022
614
0.040
 Why?
Etanidazole
1
1998
1
0.040
 Why?
Child
8
2022
22037
0.040
 Why?
Leukemia
1
2001
238
0.040
 Why?
Enterocolitis, Pseudomembranous
1
1998
29
0.040
 Why?
Expectorants
1
1998
24
0.040
 Why?
Aurora Kinase A
1
2018
56
0.040
 Why?
Loss of Function Mutation
1
2018
47
0.040
 Why?
Nervous System
2
1997
69
0.040
 Why?
Cross-Over Studies
1
2020
561
0.040
 Why?
Retreatment
1
2018
72
0.040
 Why?
Statistics, Nonparametric
1
1999
434
0.040
 Why?
Mediastinum
1
1998
25
0.040
 Why?
Disease Susceptibility
1
2020
344
0.040
 Why?
Nausea
1
2018
115
0.040
 Why?
Epithelial Cell Adhesion Molecule
1
2017
13
0.040
 Why?
Myelin Basic Protein
1
2017
47
0.040
 Why?
ADAM17 Protein
1
2017
35
0.040
 Why?
Administration, Intravenous
1
2018
154
0.040
 Why?
Extremities
2
1989
130
0.040
 Why?
Bromodeoxyuridine
1
2017
80
0.040
 Why?
Watchful Waiting
1
2018
80
0.030
 Why?
SEER Program
1
2018
218
0.030
 Why?
Breast
1
2018
153
0.030
 Why?
Medicare
1
2023
747
0.030
 Why?
Ganglia, Spinal
1
2017
77
0.030
 Why?
Diarrhea
1
2018
183
0.030
 Why?
Cell Hypoxia
1
1998
227
0.030
 Why?
Double-Blind Method
1
2022
1987
0.030
 Why?
Thorax
1
1997
47
0.030
 Why?
Random Allocation
2
1988
357
0.030
 Why?
Ascorbic Acid
1
2017
123
0.030
 Why?
Phosphoramide Mustards
1
2016
2
0.030
 Why?
Everolimus
1
2017
91
0.030
 Why?
Coculture Techniques
1
2017
240
0.030
 Why?
Heterografts
1
2017
139
0.030
 Why?
Cyclohexanes
1
2016
21
0.030
 Why?
Immunotoxins
1
1997
55
0.030
 Why?
Cohort Studies
4
2001
5730
0.030
 Why?
Cytochrome P-450 CYP3A
1
2017
88
0.030
 Why?
Cells, Cultured
2
2017
4206
0.030
 Why?
Cell Survival
1
2000
1122
0.030
 Why?
Placebos
1
2016
207
0.030
 Why?
Gene Knockdown Techniques
1
2017
329
0.030
 Why?
Fluorescence Resonance Energy Transfer
1
2017
177
0.030
 Why?
Lymphoma, Large B-Cell, Diffuse
1
1998
125
0.030
 Why?
Carcinogenesis
1
2018
220
0.030
 Why?
Injections, Intravenous
2
1993
208
0.030
 Why?
Antineoplastic Agents, Immunological
1
2018
191
0.030
 Why?
Fertility Preservation
1
2016
49
0.030
 Why?
Blood Specimen Collection
1
1995
38
0.030
 Why?
Organoplatinum Compounds
3
1990
46
0.030
 Why?
Antidotes
1
1997
143
0.030
 Why?
Blood Component Transfusion
2
1994
84
0.030
 Why?
Digestive System
1
1995
28
0.030
 Why?
Animals, Newborn
1
2017
845
0.030
 Why?
Genetic Therapy
1
1997
296
0.030
 Why?
Transcriptional Activation
1
2017
379
0.030
 Why?
Mortality
1
1997
357
0.030
 Why?
Vincristine
1
1995
116
0.030
 Why?
Fertility
1
2016
160
0.030
 Why?
Interleukin-3
1
1994
25
0.030
 Why?
Weight Gain
1
2018
518
0.030
 Why?
Hormones
1
2015
143
0.030
 Why?
Kidney
2
1995
1472
0.030
 Why?
Diagnosis, Differential
1
2019
1486
0.030
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2017
252
0.030
 Why?
Pulmonary Fibrosis
3
1993
400
0.030
 Why?
Child, Preschool
6
2013
11097
0.030
 Why?
Tosyl Compounds
1
2014
15
0.030
 Why?
Leukocyte Count
5
1996
331
0.030
 Why?
Odds Ratio
1
2017
1063
0.030
 Why?
Bacterial Infections
1
1996
251
0.030
 Why?
Adipose Tissue
1
2018
624
0.030
 Why?
Drug Discovery
1
2015
141
0.030
 Why?
Hand-Foot Syndrome
1
2013
2
0.030
 Why?
Antioxidants
1
2017
577
0.030
 Why?
Protein Transport
1
2015
443
0.030
 Why?
Capecitabine
1
2013
46
0.030
 Why?
HEK293 Cells
1
2016
734
0.030
 Why?
Transplantation, Heterologous
1
2014
195
0.030
 Why?
Neoplasm Transplantation
1
2014
256
0.030
 Why?
Necrosis
1
2014
244
0.030
 Why?
Alternative Splicing
1
2015
227
0.030
 Why?
Cell Nucleus
1
2016
615
0.030
 Why?
Erythropoietin
1
1994
95
0.030
 Why?
Gene Silencing
1
2014
195
0.030
 Why?
Binding Sites
1
2016
1310
0.030
 Why?
Blood Cells
1
1993
40
0.030
 Why?
Cross-Sectional Studies
1
2024
5427
0.030
 Why?
Nutritional Status
1
2015
344
0.020
 Why?
CD24 Antigen
1
2012
20
0.020
 Why?
Emergency Medical Services
1
2019
548
0.020
 Why?
Recombinant Proteins
5
1997
1357
0.020
 Why?
Anemia
1
1994
171
0.020
 Why?
Sensitivity and Specificity
2
2000
1950
0.020
 Why?
Radionuclide Imaging
1
1992
119
0.020
 Why?
Diet, Reducing
1
2012
88
0.020
 Why?
Energy Intake
1
2015
478
0.020
 Why?
Psychotherapy, Group
1
2012
66
0.020
 Why?
Models, Biological
1
1999
1775
0.020
 Why?
Antigens, CD34
3
1996
88
0.020
 Why?
Hyaluronan Receptors
1
2012
103
0.020
 Why?
Counseling
1
2015
393
0.020
 Why?
Feasibility Studies
4
1998
950
0.020
 Why?
Vascular Endothelial Growth Factor Receptor-1
1
2012
71
0.020
 Why?
Surveys and Questionnaires
1
2024
5772
0.020
 Why?
Mice, SCID
1
2012
367
0.020
 Why?
Pandemics
1
2020
1619
0.020
 Why?
Tumor Burden
1
2012
311
0.020
 Why?
Fluorescent Antibody Technique
2
1990
386
0.020
 Why?
Logistic Models
1
2016
2064
0.020
 Why?
Biopsy, Needle
1
2011
191
0.020
 Why?
Mice, Inbred NOD
1
2012
601
0.020
 Why?
Chromosomes, Human, Pair 9
1
1990
42
0.020
 Why?
Blast Crisis
1
1990
33
0.020
 Why?
Disease Models, Animal
1
2021
4295
0.020
 Why?
Colorado
1
2020
4521
0.020
 Why?
Bilirubin
2
2002
97
0.020
 Why?
Chromosomes, Human, Pair 22
1
1990
45
0.020
 Why?
Immunoblotting
1
2010
307
0.020
 Why?
Pemetrexed
1
2010
33
0.020
 Why?
Health Status
1
2015
784
0.020
 Why?
Glutamates
1
2010
59
0.020
 Why?
Magnetics
1
1990
47
0.020
 Why?
Antibodies, Anti-Idiotypic
1
1990
59
0.020
 Why?
Graft Survival
1
1993
540
0.020
 Why?
Gene Regulatory Networks
1
2012
308
0.020
 Why?
Urologic Diseases
1
1990
41
0.020
 Why?
Guanine
1
2010
79
0.020
 Why?
Multiple Organ Failure
2
2002
127
0.020
 Why?
Cytokines
1
1998
2095
0.020
 Why?
Kidney Diseases
2
1991
407
0.020
 Why?
Real-Time Polymerase Chain Reaction
1
2010
344
0.020
 Why?
Health Behavior
1
2015
764
0.020
 Why?
Microspheres
1
1990
137
0.020
 Why?
Spinal Cord Neoplasms
1
1989
37
0.020
 Why?
RNA, Messenger
1
2017
2838
0.020
 Why?
Chromosome Aberrations
1
1990
157
0.020
 Why?
Cell Movement
1
2014
972
0.020
 Why?
Blood
1
1990
106
0.020
 Why?
Clone Cells
1
1990
266
0.020
 Why?
Pregnancy Trimester, Second
1
2009
79
0.020
 Why?
Promoter Regions, Genetic
1
2014
1255
0.020
 Why?
Central Nervous System Diseases
1
1990
70
0.020
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
1990
121
0.020
 Why?
Hematuria
1
1989
12
0.020
 Why?
Lymphoma
1
1990
207
0.020
 Why?
Vinblastine
2
2001
71
0.020
 Why?
Hypertension
1
2018
1293
0.020
 Why?
False Negative Reactions
1
1988
54
0.020
 Why?
Creatinine
1
1991
501
0.020
 Why?
Rats
1
2017
5676
0.020
 Why?
DNA Methylation
1
2014
644
0.020
 Why?
Pregnancy Trimester, First
1
2009
142
0.020
 Why?
Niacinamide
1
2009
79
0.020
 Why?
Leukopenia
1
1988
31
0.020
 Why?
Immunophenotyping
2
2000
321
0.020
 Why?
Apoptosis Regulatory Proteins
1
2009
188
0.020
 Why?
Phenylurea Compounds
1
2009
95
0.020
 Why?
False Positive Reactions
1
1988
117
0.020
 Why?
Hospitals, Veterans
1
2009
248
0.020
 Why?
Histones
1
2014
641
0.020
 Why?
Electrophoresis
1
1988
33
0.020
 Why?
Neurons
1
2017
1613
0.020
 Why?
Antigens, Differentiation
1
1988
83
0.020
 Why?
Perilipin-1
1
2008
17
0.020
 Why?
Drug Interactions
1
1990
409
0.020
 Why?
Estrogen Receptor Modulators
1
2008
17
0.020
 Why?
Staining and Labeling
1
1988
146
0.020
 Why?
Exercise Therapy
1
2012
435
0.020
 Why?
Transfection
1
2010
948
0.020
 Why?
Macrophages
2
1995
1548
0.020
 Why?
S100 Proteins
1
2008
37
0.020
 Why?
Antigens, Surface
1
1988
154
0.020
 Why?
Gene Expression Regulation
1
2017
2615
0.020
 Why?
Vimentin
1
1988
52
0.020
 Why?
Nervous System Diseases
1
1991
265
0.020
 Why?
Community Health Services
1
2009
232
0.020
 Why?
Androstadienes
1
2008
107
0.020
 Why?
Central Nervous System
1
1990
261
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2420
0.020
 Why?
Sarcoma, Kaposi
1
1988
78
0.020
 Why?
Bone Marrow Purging
2
1996
3
0.020
 Why?
Lung Diseases
2
1992
768
0.020
 Why?
Clinical Trials, Phase II as Topic
2
2000
75
0.020
 Why?
Health Knowledge, Attitudes, Practice
1
2015
1332
0.020
 Why?
Academic Medical Centers
1
2009
498
0.020
 Why?
Biomarkers
1
2018
4172
0.020
 Why?
Risk
2
2000
905
0.020
 Why?
Heart Diseases
1
1990
359
0.020
 Why?
Stem Cell Transplantation
1
2007
177
0.020
 Why?
Gastrointestinal Diseases
1
2008
210
0.020
 Why?
Phosphoproteins
1
2008
338
0.020
 Why?
Bevacizumab
1
2006
137
0.020
 Why?
Immunoglobulin G
1
1990
886
0.020
 Why?
Quality of Health Care
1
2009
627
0.010
 Why?
Body Mass Index
1
2012
2369
0.010
 Why?
Melanoma
2
1988
758
0.010
 Why?
Carrier Proteins
1
2008
770
0.010
 Why?
Ascites
1
2002
46
0.010
 Why?
Phenotype
1
2010
3205
0.010
 Why?
Brain
1
2014
2831
0.010
 Why?
Carcinoma, Lewis Lung
1
2001
15
0.010
 Why?
Carcinoma, Large Cell
1
2001
16
0.010
 Why?
Transplantation Conditioning
1
2002
170
0.010
 Why?
Hemorrhage
2
1998
723
0.010
 Why?
Phytohemagglutinins
1
2000
30
0.010
 Why?
CD4-CD8 Ratio
1
2000
22
0.010
 Why?
Hypersensitivity, Delayed
1
2000
28
0.010
 Why?
Lymphocyte Culture Test, Mixed
1
2000
50
0.010
 Why?
Drug Synergism
1
2001
379
0.010
 Why?
Microcomputers
1
2000
16
0.010
 Why?
Skin Tests
1
2000
101
0.010
 Why?
Graft vs Host Disease
1
2002
249
0.010
 Why?
Louisiana
1
2000
29
0.010
 Why?
Philadelphia
1
2000
49
0.010
 Why?
Immunoglobulins
1
2000
171
0.010
 Why?
Automation
1
2000
95
0.010
 Why?
Immunity
1
2000
145
0.010
 Why?
Personnel Selection
1
1980
78
0.010
 Why?
Lipopolysaccharide Receptors
1
1999
86
0.010
 Why?
Marriage
1
1980
121
0.010
 Why?
Lung
1
1992
4066
0.010
 Why?
Thalassemia
1
1998
7
0.010
 Why?
Interleukin-4
1
1999
217
0.010
 Why?
Heart Failure
1
1992
2222
0.010
 Why?
Receptors, Purinergic P1
1
1998
27
0.010
 Why?
Multicenter Studies as Topic
1
2000
308
0.010
 Why?
Microscopy, Fluorescence
1
2000
402
0.010
 Why?
Reference Values
1
2000
821
0.010
 Why?
Pilot Projects
2
1994
1703
0.010
 Why?
Acute Disease
1
2001
1008
0.010
 Why?
Infant, Newborn
1
2009
6059
0.010
 Why?
Filgrastim
1
1997
8
0.010
 Why?
Killer Cells, Natural
1
2000
446
0.010
 Why?
Adenoviruses, Human
1
1996
27
0.010
 Why?
Heparin
1
1998
259
0.010
 Why?
Lymphoma, B-Cell
1
1998
107
0.010
 Why?
Tissue Plasminogen Activator
1
1998
225
0.010
 Why?
Pregnancy
1
2009
6745
0.010
 Why?
Freezing
1
1996
91
0.010
 Why?
Lymphocyte Depletion
1
1996
135
0.010
 Why?
Lymphocyte Activation
1
2000
1150
0.010
 Why?
Genes, Reporter
1
1996
268
0.010
 Why?
Carcinoma, Squamous Cell
1
2001
683
0.010
 Why?
Drug Tolerance
1
1995
105
0.010
 Why?
Reticulocyte Count
1
1994
6
0.010
 Why?
Kidney Function Tests
1
1995
158
0.010
 Why?
Topotecan
1
1994
13
0.010
 Why?
Incidence
1
2001
2792
0.010
 Why?
Antigens, CD
1
1996
524
0.010
 Why?
Liver
1
2002
1940
0.010
 Why?
Registries
1
2002
2021
0.010
 Why?
Urinary Bladder Diseases
1
1993
19
0.010
 Why?
Glioblastoma
1
1996
344
0.010
 Why?
Heart
1
1997
660
0.010
 Why?
Boston
1
1993
92
0.010
 Why?
Flow Cytometry
1
1996
1185
0.010
 Why?
Chromatography, High Pressure Liquid
1
1995
595
0.010
 Why?
Iron
1
1994
313
0.010
 Why?
Palliative Care
1
1998
738
0.010
 Why?
Cell Line
1
1996
2852
0.010
 Why?
Immunologic Factors
1
1993
239
0.010
 Why?
Cystitis
1
1990
22
0.010
 Why?
Metabolic Clearance Rate
1
1989
117
0.000
 Why?
Introns
1
1990
256
0.000
 Why?
Platinum
1
1989
49
0.000
 Why?
Prostatic Neoplasms
1
1996
1034
0.000
 Why?
Drug Combinations
1
1990
344
0.000
 Why?
Brain Diseases
1
1990
141
0.000
 Why?
Macrophage-1 Antigen
1
1988
29
0.000
 Why?
Bone Marrow Examination
1
1988
6
0.000
 Why?
Platelet Count
1
1988
86
0.000
 Why?
Erythrocyte Count
1
1988
20
0.000
 Why?
Methods
1
1988
65
0.000
 Why?
Pelvic Neoplasms
1
1988
26
0.000
 Why?
Erythroblasts
1
1988
19
0.000
 Why?
Infant
1
2002
9467
0.000
 Why?
DNA Damage
1
1990
420
0.000
 Why?
Acute Kidney Injury
1
1995
811
0.000
 Why?
Fever
1
1988
307
0.000
 Why?
In Vitro Techniques
1
1988
1108
0.000
 Why?
Pneumonia
1
1992
638
0.000
 Why?
Statistics as Topic
1
1987
316
0.000
 Why?
Elias's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (664) concept(s)
_
Co-Authors Expand Description
See all (60) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)